SYNGAP1 and epilepsy: The patients treated had LGS (n = 62, 49.6%), DS (n = 48, 38.4%), TSC (n = 5, 4%), and other epilepsy syndromes (n = 10, 8%), including three SYNGAP1-epilepsy and three with epilepsy with migrating focal seizures in infancy (Table 1).